Ischemia

Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress

Retrieved on: 
Monday, October 30, 2023

CHATHAM, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced data from two oral presentations which were delivered recently at the American College of Surgeons (ACS) Clinical Congress 2023, and The International Pancreas and Islet Transplant Association (IPITA), the International Xenotransplantation Association (IXA), and the Cell Transplant and Regenerative Medicine Society (CTRMS) Joint Congress by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in October 2023. The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection. Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com.

Key Points: 
  • The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection.
  • Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com .
  • include data demonstrating the use of TNX-1500 as maintenance therapy after xeno heart transplant in non-human primates.
  • In both studies, genetically engineered (GE) pigs in baboon transplants were treated with cold-perfused ischemia minimization and a novel costimulation-based immunosuppressive regimen including TNX-1500.

Vibrato Medical Announces Positive Results for Early Feasibility Study of Wearable, Non-Invasive Therapeutic Ultrasound to Treat Chronic Limb-Threatening Ischemia (CLTI)

Retrieved on: 
Wednesday, November 1, 2023

Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chronic Limb-Threatening Ischemia (CLTI) has successfully met its endpoint.

Key Points: 
  • Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chronic Limb-Threatening Ischemia (CLTI) has successfully met its endpoint.
  • The study evaluated patients with infrapopliteal PAD and measured changes in foot perfusion and oxygenation as well as therapy tolerance, compliance and perception.
  • Patients in the trial had Rutherford class 3, 4 or 5 PAD, meaning severe claudication, ischemic rest pain or tissue loss including nonhealing ulcers.
  • “These early findings are promising for the future of non-invasive therapeutic options to treat chronic limb-threatening ischemia,” said Juliana Elstad, CEO at Vibrato.

A new anticoagulant in Pharmascience Canada's portfolio this fall!

Retrieved on: 
Thursday, November 2, 2023

MONTREAL, Nov. 2, 2023 /CNW/ - Pharmascience Canada launches the generic drug Prpms-RIVAROXABAN, a product fully manufactured in Canada.

Key Points: 
  • MONTREAL, Nov. 2, 2023 /CNW/ - Pharmascience Canada launches the generic drug Prpms-RIVAROXABAN, a product fully manufactured in Canada.
  • It helps prevent blood clots from forming by directly blocking the activity of a clotting factor called Factor-Xa.
  • "Pharmascience is proud and committed to serving Canadian patients through the local production of our medications!
  • mentioned Mike Dutton, Vice President, and General Manager of Pharmascience Canada.

eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference

Retrieved on: 
Thursday, October 26, 2023

Two presentations will highlight data from the company’s landmark preclinical proof of concept study for kidney transplant recently published in Nature.

Key Points: 
  • Two presentations will highlight data from the company’s landmark preclinical proof of concept study for kidney transplant recently published in Nature.
  • A third presentation will share the results of a study evaluating pancreatic islets from genetically engineered porcine donors transplanted into a mouse model.
  • “We’re thrilled to share data highlighting our lead candidate for kidney transplant, EGEN-2784, as well as additional data supporting our genome engineering platform.
  • Humanized porcine donors were genetically engineered using the Yucatan miniature pig breed to carry 69 genomic edits through CRISPR/Cas 9 technology.

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Retrieved on: 
Monday, October 2, 2023

Using this approach in a model of chronic ischemic injury we successfully achieved – for the first time – dose-dependent and durable improvements in heart function through cardiac regeneration,” said Tim Hoey, Ph.D., Chief Scientific Officer of Tenaya.

Key Points: 
  • Using this approach in a model of chronic ischemic injury we successfully achieved – for the first time – dose-dependent and durable improvements in heart function through cardiac regeneration,” said Tim Hoey, Ph.D., Chief Scientific Officer of Tenaya.
  • Tenaya researchers engineered a novel AAV capable of targeting CFs with increased infectivity compared to parental AAV serotypes.
  • As detailed in the Circulation article, this novel AAV reprogramming construct, when injected into the hearts of acute mouse MI and chronic rat MI models, achieved significant and dose-dependent improvement in cardiac functions.
  • Tenaya is continuing its cardiac reprogramming research in preclinical studies of large animals using Tenaya’s proprietary injection catheter with support from grant funding from the California Institute for Regenerative Medicine (CIRM).

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, September 26, 2023

Deletion of APOE has been demonstrated to limit disease in multiple AD models.

Key Points: 
  • Deletion of APOE has been demonstrated to limit disease in multiple AD models.
  • In preclinical AD animal models, NC181 has demonstrated differentiation from amyloid targeted therapies.
  • Key findings from the study include:
    NC181 binds to amyloid associated ApoE4, resulting in amyloid clearance and prevention of amyloid deposition in mice.
  • Additional studies to characterize NC181 as a potential therapeutic for AD and CAA are ongoing.

Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)

Retrieved on: 
Tuesday, September 26, 2023

Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure.

Key Points: 
  • Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission to initiate human clinical trials aimed at treating acute lung failure.
  • Other animal studies show potential TP508 benefit in treating acute lung injury, chronic smoke inhalation, and mitigating radiation effects on brain and other tissues.
  • “TP508 is a natural regenerative peptide that accelerates tissue repair and revascularization while modulating the inflammatory response.
  • Chrysalis is using UTMB, Houston-area, and national advisors to advance TP508 for treating pulmonary indications.

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Friday, September 22, 2023

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • This application in Turkey follows the Company’s submission of an Investigational New Drug Application to the U.S. Food and Drug Administration’s (FDA).
  • The FDA subsequently granted the Company permission to proceed with this Phase II trial in late June .
  • Of this total, the application to the MoH requests permission to recruit up to 150 patients in Turkey.

Artificial Intelligence-Driven Predictive Medical Diagnostics Company Spectral MD Announces Closing of Business Combination

Retrieved on: 
Monday, September 11, 2023

DALLAS, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced today that it will commence trading on the Nasdaq Global Market on September 12, 2023 under the ticker “MDAI” following the closing of its previously announced business combination with Rosecliff Acquisition Corp I (“Rosecliff”).

Key Points: 
  • Anchored by its internally developed DeepView® System, Spectral AI’s AI-based digital wound healing assessment in predictive medical diagnostics provides clinicians with an objective and immediate assessment of a wound’s healing potential.
  • Spectral AI has received over $130 million of U.S. Government contracts, including under the U.S. federal mass casualty countermeasures program.
  • The Company has used this funding to develop its burn indication and to expand into diabetic foot ulcers (“DFU”) and anticipated multiple other clinical indications.
  • The transaction was approved at a General Meeting of the stockholders of Spectral MD Holdings, Ltd. (“Spectral MD”) on August 31, 2023 and a Special Meeting of Rosecliff’s stockholders on September 6, 2023.

Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference

Retrieved on: 
Monday, September 11, 2023

In the study the investigational HAV is being evaluated in patients with chronic limb-threatening ischemia (CLTI), the end stage of peripheral artery disease (PAD).

Key Points: 
  • In the study the investigational HAV is being evaluated in patients with chronic limb-threatening ischemia (CLTI), the end stage of peripheral artery disease (PAD).
  • The presentation at the Midwestern Vascular Conference in Minneapolis, MN, entitled Outcomes of Arterial Bypass Using the Human Acellular Vessel (HAV) In Patients With Chronic Limb Threatening Ischemia, concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage.
  • Of these 29 patients, 97% had previously experienced unsuccessful revascularization procedures on the extremity and 21 (72%) had tissue loss or gangrene.
  • The HAV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.